LITS
LITS
NASDAQ · Biotechnology

Lite Strategy Inc

$1.18
+0.01 (+0.85%)
As of Mar 23, 10:11 PM ET ·
Financial Highlights (FY 2025)
Revenue
12.33M
Net Income
-3,474,981
Gross Margin
40.9%
Profit Margin
-28.2%
Rev Growth
+17.2%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 40.9% 40.9% 40.9%
Operating Margin -31.0% -29.2% -30.6%
Profit Margin -28.2% -22.8% -22.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 12.33M 11.14M 10.37M
Gross Profit 5.05M 4.56M 4.24M
Operating Income -3,822,472 -3,256,405 -3,174,580
Net Income -3,474,981 -2,537,744 -2,319,778
Gross Margin 40.9% 40.9% 40.9%
Operating Margin -31.0% -29.2% -30.6%
Profit Margin -28.2% -22.8% -22.4%
Rev Growth +17.2% +1.6% +25.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 10.90M 9.07M 11.40M
Total Equity 31.89M 31.43M 33.01M
D/E Ratio 0.34 0.29 0.35
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -5,324,397 -5,017,327 -4,875,631
Free Cash Flow -1,460,004 -1,340,766 -1,751,994